نتایج جستجو برای: her2 gene

تعداد نتایج: 1152029  

2015
Hei Jason Chan Haiqing Li Zheng Liu Yate-Ching Yuan Joanne Mortimer Shiuan Chen

Of all breast cancer patients, about 70% are ER+ and 10% are ER+/HER2+. The ER+/HER2+ patients have a worse outcome compared to ER+/HER2- patients. Currently there is a lack of effective prognosis biomarkers for the prediction of outcome in ER+/HER2+ patients. Genome-wide differences in ER binding between the endocrine-responsive and endocrine-resistant cells were discovered using ChIP-seq, and...

Journal: :Cancer research 2013
Suthinee Ithimakin Kathleen C Day Fayaz Malik Qin Zen Scott J Dawsey Tom F Bersano-Begey Ahmed A Quraishi Kathleen Woods Ignatoski Stephanie Daignault April Davis Christopher L Hall Nallasivam Palanisamy Amber N Heath Nader Tawakkol Tahra K Luther Shawn G Clouthier Whitney A Chadwick Mark L Day Celina G Kleer Dafydd G Thomas Daniel F Hayes Hasan Korkaya Max S Wicha

Although current breast cancer treatment guidelines limit the use of HER2-blocking agents to tumors with HER2 gene amplification, recent retrospective analyses suggest that a wider group of patients may benefit from this therapy. Using breast cancer cell lines, mouse xenograft models and matched human primary and metastatic tissues, we show that HER2 is selectively expressed in and regulates se...

Journal: :Journal of clinical pathology 2015
Laura J Tafe Heather B Steinmetz Samantha F Allen Betty J Dokus Gregory J Tsongalis

Evaluation of HER2 (ERBB2) gene amplification or protein expression is standard of care in breast (BR) and advanced stage gastro-oesophageal cancers to identify patients eligible for anti-HER2 therapies. Here, we evaluate a rapid fluorescence in situ hybridisation (FISH) technology (HER2 instant quality (IQ) FISH pharmDx Kit) for detection of HER2 in patients with BR and gastro-oesophageal canc...

Journal: :Nature Communications 2021

Abstract The receptor tyrosine kinase HER2 acts as oncogenic driver in numerous cancers. Usually, the gene is amplified, resulting overexpression, massively increased signaling and unchecked proliferation. However, tumors become frequently addicted to oncogenes hence are druggable by targeted interventions. Here, we design an anti-HER2 biparatopic tetravalent IgG fusion with a multimodal mechan...

2015
Amir Sonnenblick Sylvain Brohée Debora Fumagalli Delphine Vincent David Venet Michail Ignatiadis Roberto Salgado Gert Van den Eynden Françoise Rothé Christine Desmedt Patrick Neven Sibylle Loibl Carsten Denkert Heikki Joensuu Sherene Loi Nicolas Sirtaine Pirkko-Liisa Kellokumpu-Lehtinen Martine Piccart Christos Sotiriou

BACKGROUND The likelihood of recurrence in patients with breast cancer who have HER2-positive tumors is relatively high, although trastuzumab is a remarkably effective drug in this setting. Signal transducer and activator of transcription 3 protein (STAT3), a transcription factor that is persistently tyrosine-705 phosphorylated (pSTAT3) in response to numerous oncogenic signaling pathways, acti...

Journal: :European Journal of Cancer 2022

Background: Anti-HER2 antibody-drug conjugates (HER2-ADCs) have improved survival outcomes for HER2-overexpressing (HER2+) breast cancer (BC) patients. However, intrinsic or acquired resistance to anti-HER2 therapies remains a clinical challenge HER2+ metastatic (mBC). We sought identify mechanisms therapy and potential novel therapeutic targets overcome resistance. Materials Methods: generated...

Journal: :Cancer control : journal of the Moffitt Cancer Center 2001
N M Diaz

BACKGROUND Laboratory testing of HER2/neu in breast carcinoma has become vital to patient care following the approval of trastuzumab as the first therapy to target the HER2/neu oncoprotein. Initial clinical trials used immunohistochemistry (IHC) to test for HER2/neu overexpression in order to select patients for therapy. Fluorescence in situ hybridization (FISH), which tests for gene amplificat...

2010
M. Laé J. Couturier S. Oudard F. Radvanyi P. Beuzeboc A. Vieillefond

BACKGROUND This study assessed the human epidermal growth factor receptor-2 (HER2) protein expression and its relationship with gene amplification in invasive bladder carcinoma, using the same criteria than for breast cancer. PATIENTS AND METHODS In 1005 patients, paraffin-embedded tissues of transurethral resection or cystectomy were evaluated by immunohistochemistry (IHC), using antibodies ...

2014
Ming Chen Yan Li Zhou Ming Ai Biao Liu Xue Zheng

AIM OF THE STUDY To investigate the differences and relevance, and to evaluate the clinical significance of fluorescence in situ hybridisation and immunohistochemistry (IHC) in detecting HER2 in gastric cancer tissues. MATERIAL AND METHODS The expression of HER2 protein and the amplification of the HER2 gene in 118 gastric cancer tissues were detected by immunohistochemistry and fluorescence ...

Journal: :Cancer research 2007
Gabriela Alexe Gul S Dalgin Daniel Scanfeld Pablo Tamayo Jill P Mesirov Charles DeLisi Lyndsay Harris Nicola Barnard Maritza Martel Arnold J Levine Shridar Ganesan Gyan Bhanot

Gene expression analysis has identified biologically relevant subclasses of breast cancer. However, most classification schemes do not robustly cluster all HER2+ breast cancers, in part due to limitations and bias of clustering techniques used. In this article, we propose an alternative approach that first separates the HER2+ tumors using a gene amplification signal for Her2/neu amplicon genes ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید